C29
0.03
57.9%
M2R
0.002
-33.3%
CHM
0.003
50%
FBR
0.003
-25%
LNU
0.003
50%
VHM
0.365
-22.3%
MVF
0.855
40.2%
AUR
0.017
-19%
VEN
0.005
25%
CXU
0.018
-18.2%
ALV
0.058
23.4%
MYX
3.66
-17.8%
FRX
0.016
23.1%
GTE
0.015
-16.7%
PSL
0.034
21.4%
SCP
0.1
-16.7%
MRD
0.04
21.2%
RAS
0.032
-15.8%
GTK
8
21%
RWD
0.04
-14.9%
LAT
0.06
20%
YRL
0.26
-13.3%
VAR
0.006
20%
CMG
0.105
-12.5%
CBL
0.074
19.4%
W2V
0.007
-12.5%
QUB
4.8
17.9%
ARV
0.008
-11.1%
M7T
0.43
17.8%
BCK
0.016
-11.1%
DTZ
0.053
17.8%
EVR
0.008
-11.1%
SMM
0.014
16.7%
KLR
0.16
-11.1%
ILA
0.605
16.3%
WHK
0.008
-11.1%
EUR
0.18
16.1%
OM1
0.017
-10.5%
FRB
0.15
15.4%
SHN
0.017
-10.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759